Stocks were handily lower Friday morning after Janet Yellen and the Federal Open Market Committee (FOMC) decided to keep zero interest rates here for just a tad longer. The one trend we keep seeing is that investors routinely buy pullbacks and dips. 24/7 Wall St. reviews dozens of analyst research reports each morning to find new trading and investing ideas for its readers. Some of these analyst calls are on stocks to buy, but others cover stocks to sell or to avoid. These are this Friday’s top analyst upgrades, downgrades and initiations.
Aetna Inc. (NYSE: AET) was raised to Buy from Hold with a $140 price target (versus a $117.76 prior close) at Cantor Fitzgerald. Aetna has a consensus price target of $140.25 and a 52-week trading range of $71.81 to $134.40.
Eli Lilly & Co. (NYSE: LLY) was reiterated as Buy at Bank of America Merrill Lynch, but the price objective was raised to $108 from $101. The firm raised its Jardiance peak sales to $3.5 billion, based on such positive CV results, and the stock remains its top pick in the U.S. Major Pharma group.
Gilead Sciences Inc. (NASDAQ: GILD) was reiterated as Buy with a $150 price target at Argus. This call reflects continued strong sales of the company’s hepatitis C drugs Harvoni and Sovaldi and the upcoming launch of a new version of an existing HIV drug with an improved safety profile. The stock has a $125.39 consensus price target, and the official high price target in the Thomson Reuters universe is $141.00.
Royal Gold Inc. (NASDAQ: RGLD) was started as Outperform and was assigned a $56 price target (versus a $48.18 close) at FBR Capital Markets. Royal Gold has a $74.00 consensus price target and a 52-week range of $42.21 to $77.20.
Sirius XM Holdings Inc. (NASDAQ: SIRI) was started as Buy at Gabelli. No price target was seen. Sirius XM closed at $3.86 and has a consensus price target of $4.60 and a 52-week range of $3.14 to $4.04.
Other key analyst upgrades, downgrades and initiations seen this Friday were in the following: